Questions to the MHRA about the Properties of the Bird flu Vaccine
As suggested by the purchasers (UKHSA), as they have no clue
You may recall that the UK Health Security Agency (UKHSA) responded to another of our FOIA requests. In this request, we asked about the properties of the 5.5 million doses of H5 influenza vaccine Sequirus Ltd. purchased with our money.
Here are the questions and the reply dated 9 January 2025:
It seems strange that the UKHSA adjudicated the tender if they did not know what they bought while proposing to give the stuff to such categories as pregnant women. So, in the interest of the public, we did as we were told and sent a request to the X at xxxxxxxx@xxxx.xxx.xx.
We swiftly got an answer, acknowledging our request and promising an answer by 6 February. Let us hope that the bird “f word” will not have taken over the universe by that date.
This post was written by two old geezers who do not have dying turkeys, sick chickens or dead ducks under their beds,
Thank you for your comments. We kept that in mind when we wrote the questions. If you look at the original list we refer to a vaccine/platform. If it a platform that could fit the H5 title of the announcement. As the hemaggluttinin is fixed - 5 - and the neuraminidase changes N1, N7 and so on.
We have just finished writing the first post of the trilogy out next Monday pm and we move to looking carefully at the contract. We should get a better idea of what they bought with our cash.
Best, Tom.
Well, as Brian Finney points out, it may not yet exist. If it does, all the regulatory info. asked for above, should already be on file and if so, could be supplied with attachments, or links. It bothers me that they need, or can take 20 working days to reply to bog standard information in their line of work.